[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100503515":3},{"organization":4,"armGroups":7,"interventions":18,"overallOfficials":24,"centralContacts":25,"locations":35,"responsibleParty":163,"collaborators":24,"id":165,"slug":24,"hasResults":166,"nctId":167,"briefTitle":168,"officialTitle":169,"acronym":170,"eligibilityCriteria":171,"healthyVolunteers":166,"sex":172,"minAge":173,"maxAge":174,"enrollmentInfo":175,"targetDuration":24,"studyType":178,"phases":179,"briefSummary":182,"conditions":183,"keywords":185,"overallStatus":38,"whyStopped":24,"lastUpdateSubmitDate":196,"lastUpdatePostDateStruct":197,"startDateStruct":200,"completionDateStruct":202,"leadSponsor":204,"locationsCount":205},{"fullName":5,"class":6},"Tenaya Therapeutics","INDUSTRY",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Cohort 1","EXPERIMENTAL","Dose for Cohort 1 will be 3E13 vg\u002Fkg",[13],"Genetic: TN-201",{"label":15,"type":10,"description":16,"interventionNames":17},"Cohort 2","Dose for Cohort 2 will be 6E13 vg\u002Fkg",[13],[19],{"type":20,"name":21,"description":22,"armGroupLabels":23,"otherNames":24},"GENETIC","TN-201","TN-201 is a recombinant adeno-associated virus serotype 9 (AAV9) containing Myosin Binding Protein C (MYBPC3) transgene. It is a single (one-time) intravenous dose.",[9,15],null,[26,31],{"name":27,"role":28,"phone":29,"phoneExt":24,"email":30},"Matt Pollman, M.D.","CONTACT","650-209-8092","mpollman@tenayathera.com",{"name":32,"role":28,"phone":33,"phoneExt":24,"email":34},"LaTanya Tomlinson, RN, MHSA","650-825-6990","clinical.trials@tenayathera.com",[36,54,68,79,89,104,114,128,138,148],{"facility":37,"status":38,"city":39,"state":40,"zip":41,"country":42,"cosmosGeoPoint":43,"geoPoint":48,"contacts":49},"UC San Diego Altman Clinical and Translational Research Institute - Center for Clinical Research","RECRUITING","La Jolla","California","92093","United States",{"type":44,"coordinates":45},"Point",[46,47],-117.2742,32.84727,{"lat":47,"lon":46},[50],{"name":51,"role":28,"phone":52,"phoneExt":24,"email":53},"Matt Fahey","858-534-3798","mjfahey@health.ucsd.edu",{"facility":55,"status":38,"city":56,"state":40,"zip":57,"country":42,"cosmosGeoPoint":58,"geoPoint":62,"contacts":63},"University of California San Francisco","San Francisco","94117",{"type":44,"coordinates":59},[60,61],-122.41942,37.77493,{"lat":61,"lon":60},[64],{"name":65,"role":28,"phone":66,"phoneExt":24,"email":67},"Emma Reagan","415-514-7280","Emma.reagan@ucsf.edu",{"facility":69,"status":70,"city":71,"state":72,"zip":73,"country":42,"cosmosGeoPoint":74,"geoPoint":78,"contacts":24},"Emory University","WITHDRAWN","Atlanta","Georgia","30322",{"type":44,"coordinates":75},[76,77],-84.38798,33.749,{"lat":77,"lon":76},{"facility":80,"status":70,"city":81,"state":82,"zip":83,"country":42,"cosmosGeoPoint":84,"geoPoint":88,"contacts":24},"Brigham and Women's Hospital","Boston","Massachusetts","02115",{"type":44,"coordinates":85},[86,87],-71.05977,42.35843,{"lat":87,"lon":86},{"facility":90,"status":38,"city":91,"state":92,"zip":93,"country":42,"cosmosGeoPoint":94,"geoPoint":98,"contacts":99},"Mayo Clinic","Rochester","Minnesota","55905",{"type":44,"coordinates":95},[96,97],-92.4699,44.02163,{"lat":97,"lon":96},[100],{"name":101,"role":28,"phone":102,"phoneExt":24,"email":103},"Sierra Slade","507-422-5433","Slade.Sierra@mayo.edu",{"facility":105,"status":70,"city":106,"state":107,"zip":108,"country":42,"cosmosGeoPoint":109,"geoPoint":113,"contacts":24},"The Christ Hospital Physicians - The Ohio Heart and Vascular Center","Cincinnati","Ohio","45219",{"type":44,"coordinates":110},[111,112],-84.51439,39.12711,{"lat":112,"lon":111},{"facility":115,"status":38,"city":116,"state":107,"zip":117,"country":42,"cosmosGeoPoint":118,"geoPoint":122,"contacts":123},"Cleveland Clinic","Cleveland","44195",{"type":44,"coordinates":119},[120,121],-81.69541,41.4995,{"lat":121,"lon":120},[124],{"name":125,"role":28,"phone":126,"phoneExt":24,"email":127},"Rachael Landis","216-444-3650","LANDISR@ccf.org",{"facility":129,"status":70,"city":130,"state":131,"zip":132,"country":42,"cosmosGeoPoint":133,"geoPoint":137,"contacts":24},"Oregon Health & Science University","Portland","Oregon","97239",{"type":44,"coordinates":134},[135,136],-122.67621,45.52345,{"lat":136,"lon":135},{"facility":139,"status":70,"city":140,"state":141,"zip":142,"country":42,"cosmosGeoPoint":143,"geoPoint":147,"contacts":24},"Hospital of the University of Pennsylvania","Philadelphia","Pennsylvania","19104",{"type":44,"coordinates":144},[145,146],-75.16362,39.95238,{"lat":146,"lon":145},{"facility":149,"status":38,"city":150,"state":151,"zip":152,"country":42,"cosmosGeoPoint":153,"geoPoint":157,"contacts":158},"Houston Methodist Hospital","Houston","Texas","77030",{"type":44,"coordinates":154},[155,156],-95.36327,29.76328,{"lat":156,"lon":155},[159],{"name":160,"role":28,"phone":161,"phoneExt":24,"email":162},"Jennifer Garrett","281-222-9983","jmgarrett@houstonmethodist.org",{"type":164,"investigatorFullName":24,"investigatorTitle":24,"investigatorAffiliation":24,"oldNameTitle":24,"oldOrganization":24},"SPONSOR","100503515",false,"NCT05836259","Multi-center, Open-label, Single-ascending Dose Study of Safety and Tolerability of TN-201 in Adults With Symptomatic MYBPC3 Mutation-associated HCM","First-in-Human, Open-Label, Safety, Tolerability, Dose-Finding, Pharmacodynamic and Cardiac Transgene Expression Study of TN-201, a Recombinant Adeno-associated Virus Serotype 9 (AAV9) Containing Myosin Binding Protein C Transgene, in Adults With MYBPC3 Mutation-associated Hypertrophic Cardiomyopathy (HCM)","MyPEAK-1","Inclusion Criteria:\n\n* MYBPC3 mutation\n* Hypertrophic Cardiomyopathy (obstructive and nonobstructive)\n* Left Ventricular Ejection Fraction ≥45%\n* NYHA Functional Class II or III symptoms\n* NT-proBNP ≥160pg\u002Fml\n\nExclusion Criteria:\n\n* High AAV9 neutralizing antibody titer","ALL","18 Years","75 Years",{"count":176,"type":177},30,"ESTIMATED","INTERVENTIONAL",[180,181],"PHASE1","PHASE2","This is a first-in-human, non-randomized, open-label study designed to evaluate the safety, tolerability, and pharmacodynamics (PD) of TN-201 in adult patients with symptomatic hypertrophic cardiomyopathy (HCM) caused by mutations in the MYBPC3 gene.",[184],"Hypertrophic Cardiomyopathy",[186,187,188,189,190,191,192,193,194,195],"Hypertrophic Cardiomyopathy (HCM)","Myosin Binding Protein C3 (MYBPC3)","Nonobstructive HCM","Genetic HCM","Familial HCM","Adenoassociated Virus (AAV)","Gene Therapy","Obstructive HCM","nHCM","oHCM","2026-03-18",{"date":198,"type":199},"2026-03-19","ACTUAL",{"date":201,"type":199},"2023-08-10",{"date":203,"type":177},"2032-08",{"name":5,"class":6},10]